Abstract: TH-PO927
Effect Modification of Familial Longevity on the Association between Cardiovascular Disease and Kidney Dysfunction
Session Information
- Geriatric Nephrology: Innovations and Insights
October 24, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Geriatric Nephrology
- 1300 Geriatric Nephrology
Authors
- Alzyood, Laith, Montefiore Medical Center, New York, New York, United States
- Gao, Tina, Albert Einstein College of Medicine, Bronx, New York, United States
- Sathyan, Sanish, Albert Einstein College of Medicine, Bronx, New York, United States
- Aleksic, Sandra, Albert Einstein College of Medicine, Bronx, New York, United States
- Milman, Sofiya, Albert Einstein College of Medicine, Bronx, New York, United States
- Melamed, Michal L., New York University, New York, New York, United States
- Chen, Wei, Albert Einstein College of Medicine, Bronx, New York, United States
Background
Chronic kidney disease (CKD) is among the strongest risk factors for cardiovascular disease (CVD) and mortality. Familial longevity may protect from age-related diseases. We hypothesized that familial longevity modified the association between CKD and CVD in older adults.
Methods
LonGenity is a cohort study of community dwelling Ashkenazi Jewish adults aged 65-94 years that aims to identify genetic determinants of familial longevity by comparing offspring of parents with exceptional longevity (OPEL, n=427) with offspring of parents with usual survival (OPUS, n=404). Exceptional longevity was defined as living past the age of 95 years. GFR was estimated using serum creatinine and CKD-EPI equation. Prevalent CVD was defined as a composite of myocardial infarction, coronary artery bypass graft, percutaneous intervention, or stroke. Multiple logistic regression was used to examine the cross-sectional association between eGFR and CVD. Effect modification with familial longevity (OPEL vs. OPUS) was tested using a first-order interaction term and stratified analyses.
Results
Mean age was 76±7 years, 57% were women, 9% had diabetes, 44.5% had hypertension, and 14.6% had CVD. Mean eGFR was 73 and 69 ml/min/1.73m2 in OPEL and OPUS, respectively. Familial longevity did not significantly modify the association between eGFR and CVD (p for interaction=0.99). In stratified analyses, after adjusting for age, sex, physical activity, hypertension, diabetes, and body mass index, the odds ratio for having CVD was 0.94 (95% CI: 0.84-1.04) for every 5 mL/min/1.73m2 higher eGFR among OPEL and 0.94 (95% CI: 0.86-1.02) for OPUS.
Conclusion
In this unique cohort, we found that familial longevity did not significantly modify the association between eGFR and CVD prevalence. Further studies are needed to examine whether kidney disease predicts the incidence or progression of CVD.
Multiple Logistic Regression Analysis Stratified by Familial Longevity
| Odds Ratio (95%CI) | P-value | |
| OPEL (n=427) | CVD events=41 | |
| eGFR, 5mL/min/1.73m2 Age, 5 years Female Walking endurance>30 min Hypertension Diabetes Obese, BMI>30 | 0.94 (0.84-1.05) 1.41 (1.05-1.90) 0.12 (0.05-0.29) 0.43 (0.19-0.99) 1.94 (0.93-4.03) 1.22 (0.39-3.84) 1.05 (0.46-2.36) | 0.25 0.02 <0.01 0.05 0.08 0.73 0.92 |
| OPUS(n=404) | CVD events=75 | |
| eGFR, 5mL/min/1.73m2 Age, 5 years Female Walking endurance>30 min Hypertension Diabetes Obese, BMI>30 | 0.94 (0.86-1.02) 1.46 (1.14-1.87) 0.11 (0.06-0.23) 0.59 (0.30,1.15) 1.88 (1.01-3.51) 1.55 (0.66-3.64) 1.39 (0.72-2.71) | 0.14 <0.01 <0.01 0.12 0.05 0.31 0.33 |
Funding
- NIDDK Support